{"id":9980,"date":"2026-09-02T13:25:06","date_gmt":"2026-09-02T18:25:06","guid":{"rendered":"https:\/\/fifarma.org\/?p=9980"},"modified":"2026-09-02T13:25:07","modified_gmt":"2026-09-02T18:25:07","slug":"access-to-innovation-in-latin-america-wait-2026","status":"publish","type":"post","link":"https:\/\/fifarma.org\/en\/access-to-innovation-in-latin-america-wait-2026\/","title":{"rendered":"FIFARMA W.A.I.T. Indicator 2026: from waiting time to an opportunity to move forward"},"content":{"rendered":"<p class=\"wp-block-yoast-seo-estimated-reading-time yoast-reading-time__wrapper\"><span class=\"yoast-reading-time__icon\"><svg aria-hidden=\"true\" focusable=\"false\" data-icon=\"clock\" width=\"20\" height=\"20\" fill=\"none\" stroke=\"currentColor\" style=\"display:inline-block;vertical-align:-0.1em\" role=\"img\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewbox=\"0 0 24 24\"><path stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\"2\" d=\"M12 8v4l3 3m6-3a9 9 0 11-18 0 9 9 0 0118 0z\"><\/path><\/svg><\/span><span class=\"yoast-reading-time__spacer\" style=\"display:inline-block;width:1em\"><\/span><span class=\"yoast-reading-time__descriptive-text\">Estimated reading time: <\/span><span class=\"yoast-reading-time__reading-time\">4<\/span><span class=\"yoast-reading-time__time-unit\"> minutes<\/span><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A patient in Latin America waits an average of <strong>5,7 years<\/strong> from the moment an innovative medicine is approved in the United States or Europe until they can access it in their own country. That is the central finding of the <strong>FIFARMA W.A.I.T. Indicator 2026<\/strong>, developed with IQVIA and covering 447 innovative molecules approved between 2014 and 2025 across ten countries that account for more than 80% of the region&#8217;s population.<\/p>\n\n\n\n<h2 id=\"h-measuring-the-distance-between-innovation-and-the-patient\" class=\"wp-block-heading\" style=\"font-size:22px\">Measuring the distance between innovation and the patient<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Measuring that distance is the first step toward closing it. The wait breaks down into two stages: 36 months (3 years) until local regulatory approval \u2014 including submission times \u2014 and another 32 months (2.7 years) until the treatment is actually available. In total, 68 months in which the innovation exists and is already approved elsewhere in the world yet still does not reach the people who need it.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The gap keeps growing: the regional average went from 4.5 years in 2023 to 4.8 in 2024, 5.6 in 2025 and 5.7 in 2026. What matters is where the bottleneck has moved: while regulatory timelines improved by as much as 5% in some cases, post-approval delays grew by 10%. Today, the greatest opportunity lies in moving toward more sustainable, value-based solutions that help new treatments reach the people waiting for them.<\/p>\n\n\n\n<h2 id=\"h-how-long-access-to-innovative-therapies-takes-in-each-country\" class=\"wp-block-heading\" style=\"font-size:22px\">How long access to innovative therapies takes in each country?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Each country has its own starting point and concrete opportunities to move toward more timely access:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong><em>Country<\/em><\/strong><\/td><td><strong><em>Access time<\/em><\/strong><\/td><td><strong><em>Country<\/em><\/strong><\/td><td><strong><em>Access time<\/em><\/strong><\/td><\/tr><tr><td><strong>Argentina<\/strong><\/td><td>5,3 years<\/td><td><strong>Ecuador<\/strong><\/td><td>5,8 years<\/td><\/tr><tr><td><strong>Brazil<\/strong><\/td><td>5,5 years<\/td><td><strong>Dominican Rep.<\/strong><\/td><td>5,9 years<\/td><\/tr><tr><td><strong>Peru<\/strong><\/td><td>5,5 years<\/td><td><strong>Chile<\/strong><\/td><td>7,1 years<\/td><\/tr><tr><td><strong>Colombia<\/strong><\/td><td>5,7 years<\/td><td><strong>Costa Rica<\/strong><\/td><td>7,3 years<\/td><\/tr><tr><td><strong>Mexico<\/strong><\/td><td>5,8 years<\/td><td><strong>Panama<\/strong><\/td><td>7,6 years<\/td><\/tr><\/tbody><\/table><figcaption class=\"wp-element-caption\"><em>Source: <a href=\"https:\/\/fifarma.org\/en\/publications\/fifarma-patient-wait-indicator-2026\/\" target=\"_blank\" rel=\"noreferrer noopener\">FIFARMA W.A.I.T. Indicator 2026 (IQVIA)<\/a>, times measured from global approval.<\/em><\/figcaption><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Argentina leads with the shortest waiting time; Brazil records the fastest regulatory approval of the ten markets; Peru is the country that reaches the patient most quickly once a treatment has been approved; and Mexico achieves the highest level of full availability in the region.<\/p>\n\n\n\n<h2 id=\"h-the-road-from-approval-to-access\" class=\"wp-block-heading\" style=\"font-size:22px\">The road from approval to access<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Only 60% of the molecules analyzed reach the region. Regulatory approval, however, is only part of the journey: just 34% achieve full availability with broad reimbursement. The rest is split between limited availability (21%), access through the private market only (27%) and molecules that are approved but not yet available (18%). These differences point to a key opportunity for the region: advancing toward mechanisms that turn approval into effective patient access more quickly, regardless of the health system a patient belongs to.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The gaps also vary by therapeutic area. Oncology shows the highest levels of access, although only 27% of its molecules reach full availability and 18% are available exclusively through private channels. By contrast, central nervous system therapies register barely 14% full availability.<\/p>\n\n\n\n<h2 id=\"h-health-is-not-an-expense-it-is-an-investment\" class=\"wp-block-heading\" style=\"font-size:22px\">Health is not an expense: it is an investment<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The study is clear in its diagnosis: the gap is not caused by a lack of innovation, but by <strong>the distance between the pace at which innovation advances and the capacity of health systems to incorporate it<\/strong>. Public health spending in the region averages 4.4% of GDP, below the 6% recommended by the WHO and the 6.5% of OECD countries. For innovative therapies the distance doubles: 0.19% of GDP compared with 0.44% in OECD countries..<\/p>\n\n\n\n<blockquote class=\"wp-block-quote\">\n  \n<p lang=\"en\">\u201cHealth is not a priority; it is seen more as a burden or an expense, rather than what it should be: an investment.\u201d<\/p>\n  \n<cite>\n    <strong>\u2014 Former Minister of Health, interviewed for the FIFARMA W.A.I.T. Indicator 2026<\/strong>\n  <\/cite>\n<\/blockquote>\n\n\n\n<p class=\"wp-block-paragraph\">Insufficient investment in health does not only limit access to new therapies; it also reduces the capacity of systems to assess and incorporate them efficiently. This can lead to more fragmented processes, longer delays and less predictable access routes, such as litigation.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">The challenge will be even greater in the years ahead. With an aging population and the rise of chronic diseases, health spending in the region is projected to grow from the current 7.4% of GDP to around 9.3% by 2050. <strong>Investing better today also means preparing health systems to respond more sustainably to the needs of the future.<\/strong><\/p>\n<\/blockquote>\n\n\n\n<h2 id=\"h-the-way-forward-collaboration-technology-and-planning\" class=\"wp-block-heading\" style=\"font-size:22px\">The way forward: collaboration, technology and planning<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The region already has progress to build on. Six Latin American regulatory agencies \u2014 COFEPRIS, ANVISA, INVIMA, ISPCH, ARCSA and ANMAT \u2014 are now recognized by PAHO as National Regional Reference Authorities, strengthening the conditions to advance reliance mechanisms and move toward faster, more predictable approval processes. Building on this, the report identifies three opportunities to accelerate access: strengthening collaboration between countries and institutions, integrating new technologies such as artificial intelligence into regulatory and assessment processes, and anticipating health system needs in order to prioritize the therapies with the greatest impact.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote\">\n  \n<p lang=\"en\">\u201cEducating and facilitating access to information allows us to identify where the main bottlenecks are. Recognizing them is the first step toward working together and continuing to move toward health systems with greater access and better outcomes.\u201d<\/p>\n  \n<cite>\n    <strong>\u2014 Vitor Nasciben, Co-chair of the FIFARMA access group<\/strong>\n  <\/cite>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote\">\n  \n<p lang=\"en\">\u201cThe opportunity lies in sharing and making care pathways more visible, so that every patient knows how to reach the treatment they need in time \u2014 especially when time is decisive, as it is in oncology.\u201d<\/p>\n  \n<cite>\n    <strong>\u2014 Alejandra Toro, Founder of Corporaci\u00f3n Luz Rosa<\/strong>\n  <\/cite>\n<\/blockquote>\n\n\n\n<p class=\"wp-block-paragraph\">Behind every month of waiting there are patients who need an answer. Closing the 5.7 years that <strong>today separate innovation from those who need it requires turning evidence into action, strengthening health systems and moving toward decisions that enable more timely and sustainable access.<\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>A patient in Latin America waits an average of 5,7 years from the moment an innovative medicine is approved in the United States or Europe until they can access it in their own country. That is the central finding of the FIFARMA W.A.I.T. Indicator 2026, developed with IQVIA and covering 447 innovative molecules approved between [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":9973,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[153],"tags":[122],"class_list":["post-9980","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-acceso","tag-w-a-i-t-indicator"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.2 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Access to Innovation in Latin America: W.A.I.T. 2026<\/title>\n<meta name=\"description\" content=\"FIFARMA W.A.I.T. 2026: Access to innovation in Latin America takes an average of 5.7 years. Discover the regional data and key insights.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fifarma.org\/en\/access-to-innovation-in-latin-america-wait-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FIFARMA W.A.I.T. Indicator 2026: from waiting time to an opportunity to move forward\" \/>\n<meta property=\"og:description\" content=\"FIFARMA W.A.I.T. 2026: Access to innovation in Latin America takes an average of 5.7 years. Discover the regional data and key insights.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fifarma.org\/en\/access-to-innovation-in-latin-america-wait-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"FIFARMA\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-02T18:25:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-02T18:25:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fifarma.org\/wp-content\/uploads\/2026\/08\/blog_wait_2026_eng-scaled.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"fifarmacomunicaciones\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"fifarmacomunicaciones\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":[\"Article\",\"Report\"],\"@id\":\"https:\\\/\\\/fifarma.org\\\/access-to-innovation-in-latin-america-wait-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/access-to-innovation-in-latin-america-wait-2026\\\/\"},\"author\":{\"name\":\"fifarmacomunicaciones\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/person\\\/f1731f7484686defa417316a8fe42068\"},\"headline\":\"FIFARMA W.A.I.T. Indicator 2026: from waiting time to an opportunity to move forward\",\"datePublished\":\"2026-09-02T18:25:06+00:00\",\"dateModified\":\"2026-09-02T18:25:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/access-to-innovation-in-latin-america-wait-2026\\\/\"},\"wordCount\":892,\"publisher\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/access-to-innovation-in-latin-america-wait-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/blog_wait_2026_eng-scaled.png\",\"keywords\":[\"W.A.I.T. Indicator\"],\"articleSection\":[\"Acceso\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/access-to-innovation-in-latin-america-wait-2026\\\/\",\"url\":\"https:\\\/\\\/fifarma.org\\\/access-to-innovation-in-latin-america-wait-2026\\\/\",\"name\":\"Access to Innovation in Latin America: W.A.I.T. 2026\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/access-to-innovation-in-latin-america-wait-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/access-to-innovation-in-latin-america-wait-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/blog_wait_2026_eng-scaled.png\",\"datePublished\":\"2026-09-02T18:25:06+00:00\",\"dateModified\":\"2026-09-02T18:25:07+00:00\",\"description\":\"FIFARMA W.A.I.T. 2026: Access to innovation in Latin America takes an average of 5.7 years. Discover the regional data and key insights.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/access-to-innovation-in-latin-america-wait-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fifarma.org\\\/access-to-innovation-in-latin-america-wait-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/access-to-innovation-in-latin-america-wait-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/blog_wait_2026_eng-scaled.png\",\"contentUrl\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/blog_wait_2026_eng-scaled.png\",\"width\":2560,\"height\":1280,\"caption\":\"From Waiting Time to the Oportunity to Move Forward\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/access-to-innovation-in-latin-america-wait-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/fifarma.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FIFARMA W.A.I.T. Indicator 2026: from waiting time to an opportunity to move forward\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#website\",\"url\":\"https:\\\/\\\/fifarma.org\\\/\",\"name\":\"FIFARMA\",\"description\":\"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica\",\"publisher\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fifarma.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\",\"name\":\"Fifarma\",\"alternateName\":\"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica\",\"url\":\"https:\\\/\\\/fifarma.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/logo-fifarma.png\",\"contentUrl\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/logo-fifarma.png\",\"width\":195,\"height\":39,\"caption\":\"Fifarma\"},\"image\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/person\\\/f1731f7484686defa417316a8fe42068\",\"name\":\"fifarmacomunicaciones\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8af54b74d81934872c5e9bf852bec4021ca6d3043cf2132e25087b2d09318d1c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8af54b74d81934872c5e9bf852bec4021ca6d3043cf2132e25087b2d09318d1c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8af54b74d81934872c5e9bf852bec4021ca6d3043cf2132e25087b2d09318d1c?s=96&d=mm&r=g\",\"caption\":\"fifarmacomunicaciones\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Access to Innovation in Latin America: W.A.I.T. 2026","description":"FIFARMA W.A.I.T. 2026: Access to innovation in Latin America takes an average of 5.7 years. Discover the regional data and key insights.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fifarma.org\/en\/access-to-innovation-in-latin-america-wait-2026\/","og_locale":"en_US","og_type":"article","og_title":"FIFARMA W.A.I.T. Indicator 2026: from waiting time to an opportunity to move forward","og_description":"FIFARMA W.A.I.T. 2026: Access to innovation in Latin America takes an average of 5.7 years. Discover the regional data and key insights.","og_url":"https:\/\/fifarma.org\/en\/access-to-innovation-in-latin-america-wait-2026\/","og_site_name":"FIFARMA","article_published_time":"2026-09-02T18:25:06+00:00","article_modified_time":"2026-09-02T18:25:07+00:00","og_image":[{"width":2560,"height":1280,"url":"https:\/\/fifarma.org\/wp-content\/uploads\/2026\/08\/blog_wait_2026_eng-scaled.png","type":"image\/png"}],"author":"fifarmacomunicaciones","twitter_card":"summary_large_image","twitter_misc":{"Written by":"fifarmacomunicaciones","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["Article","Report"],"@id":"https:\/\/fifarma.org\/access-to-innovation-in-latin-america-wait-2026\/#article","isPartOf":{"@id":"https:\/\/fifarma.org\/access-to-innovation-in-latin-america-wait-2026\/"},"author":{"name":"fifarmacomunicaciones","@id":"https:\/\/fifarma.org\/#\/schema\/person\/f1731f7484686defa417316a8fe42068"},"headline":"FIFARMA W.A.I.T. Indicator 2026: from waiting time to an opportunity to move forward","datePublished":"2026-09-02T18:25:06+00:00","dateModified":"2026-09-02T18:25:07+00:00","mainEntityOfPage":{"@id":"https:\/\/fifarma.org\/access-to-innovation-in-latin-america-wait-2026\/"},"wordCount":892,"publisher":{"@id":"https:\/\/fifarma.org\/#organization"},"image":{"@id":"https:\/\/fifarma.org\/access-to-innovation-in-latin-america-wait-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/fifarma.org\/wp-content\/uploads\/2026\/08\/blog_wait_2026_eng-scaled.png","keywords":["W.A.I.T. Indicator"],"articleSection":["Acceso"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/fifarma.org\/access-to-innovation-in-latin-america-wait-2026\/","url":"https:\/\/fifarma.org\/access-to-innovation-in-latin-america-wait-2026\/","name":"Access to Innovation in Latin America: W.A.I.T. 2026","isPartOf":{"@id":"https:\/\/fifarma.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fifarma.org\/access-to-innovation-in-latin-america-wait-2026\/#primaryimage"},"image":{"@id":"https:\/\/fifarma.org\/access-to-innovation-in-latin-america-wait-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/fifarma.org\/wp-content\/uploads\/2026\/08\/blog_wait_2026_eng-scaled.png","datePublished":"2026-09-02T18:25:06+00:00","dateModified":"2026-09-02T18:25:07+00:00","description":"FIFARMA W.A.I.T. 2026: Access to innovation in Latin America takes an average of 5.7 years. Discover the regional data and key insights.","breadcrumb":{"@id":"https:\/\/fifarma.org\/access-to-innovation-in-latin-america-wait-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fifarma.org\/access-to-innovation-in-latin-america-wait-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fifarma.org\/access-to-innovation-in-latin-america-wait-2026\/#primaryimage","url":"https:\/\/fifarma.org\/wp-content\/uploads\/2026\/08\/blog_wait_2026_eng-scaled.png","contentUrl":"https:\/\/fifarma.org\/wp-content\/uploads\/2026\/08\/blog_wait_2026_eng-scaled.png","width":2560,"height":1280,"caption":"From Waiting Time to the Oportunity to Move Forward"},{"@type":"BreadcrumbList","@id":"https:\/\/fifarma.org\/access-to-innovation-in-latin-america-wait-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/fifarma.org\/"},{"@type":"ListItem","position":2,"name":"FIFARMA W.A.I.T. Indicator 2026: from waiting time to an opportunity to move forward"}]},{"@type":"WebSite","@id":"https:\/\/fifarma.org\/#website","url":"https:\/\/fifarma.org\/","name":"FIFARMA","description":"Latin American Federation of the Pharmaceutical Industry","publisher":{"@id":"https:\/\/fifarma.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fifarma.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fifarma.org\/#organization","name":"Fifarma","alternateName":"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica","url":"https:\/\/fifarma.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fifarma.org\/#\/schema\/logo\/image\/","url":"https:\/\/fifarma.org\/wp-content\/uploads\/2022\/10\/logo-fifarma.png","contentUrl":"https:\/\/fifarma.org\/wp-content\/uploads\/2022\/10\/logo-fifarma.png","width":195,"height":39,"caption":"Fifarma"},"image":{"@id":"https:\/\/fifarma.org\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/fifarma.org\/#\/schema\/person\/f1731f7484686defa417316a8fe42068","name":"fifarmacomunicaciones","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/8af54b74d81934872c5e9bf852bec4021ca6d3043cf2132e25087b2d09318d1c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8af54b74d81934872c5e9bf852bec4021ca6d3043cf2132e25087b2d09318d1c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8af54b74d81934872c5e9bf852bec4021ca6d3043cf2132e25087b2d09318d1c?s=96&d=mm&r=g","caption":"fifarmacomunicaciones"}}]}},"_links":{"self":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/posts\/9980","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/comments?post=9980"}],"version-history":[{"count":1,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/posts\/9980\/revisions"}],"predecessor-version":[{"id":9981,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/posts\/9980\/revisions\/9981"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/media\/9973"}],"wp:attachment":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/media?parent=9980"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/categories?post=9980"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/tags?post=9980"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}